CD19 and neoplasm: The remaining 42 (79%) patients received anti-CD19-CAR-T therapy, among which, 25 patients (the combined group) had at least one report of high tumor bulk (tumor diameter ≥7.5 cm), another 17 patients (the control group) without high tumor bulk who received the same anti-CD19-CAR-T therapy were included as controls (Figure 2).